One strength of our investigation is the simultaneous evaluation of an index of drug exposure (5FU CL) and of several TYMS and MTHFR polymorphisms possibly related to tumour sensitivity, in a group of patients homogeneously treated with a repeated bolus regimen. Here, MTHFR is linked to neoplasm.